161 related articles for article (PubMed ID: 32364409)
1. Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm.
Blum S; Dunet V; Comoli P; Tirefort Y; Chalandon Y; Opota O; Comte D; Spertini O; Livio F; Brouland JP; Du Pasquier R
Leuk Lymphoma; 2020 Sep; 61(9):2226-2229. PubMed ID: 32364409
[No Abstract] [Full Text] [Related]
2. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene.
García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM
Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041
[No Abstract] [Full Text] [Related]
3. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
Coltro G; Santi R
Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
[No Abstract] [Full Text] [Related]
4. [Acute myeloid leukemia with FIP1L1-PDGFRA fusion gene treated with imatinib: a case report and literature review].
Fan JC; You WW; Liu HX; Cai Y; Du X; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1044-1046. PubMed ID: 33445855
[No Abstract] [Full Text] [Related]
5. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S
Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910
[No Abstract] [Full Text] [Related]
6. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
[No Abstract] [Full Text] [Related]
7. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
Ng HJ; Tan DC; Yiu RC; How GF
Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
[TBL] [Abstract][Full Text] [Related]
8. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV
Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920
[No Abstract] [Full Text] [Related]
9. Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report.
Lv Y; Yao X; Ling Q; Suo S; Wang J; Zhao S; Gao X; Tong H; Jin J; Zhang X; Yu W
Ann Hematol; 2024 Jan; 103(1):357-360. PubMed ID: 37777636
[No Abstract] [Full Text] [Related]
10. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
11. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
Srinivasan A; Scordino T; Baker A
J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397
[No Abstract] [Full Text] [Related]
12. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
13. Detection of FIP1L1-PDGFRA fusion by FISH.
Ma ES; Wong KF; Wong CL; Siu LL
Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
[No Abstract] [Full Text] [Related]
14. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
Borbényi Z
Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
[TBL] [Abstract][Full Text] [Related]
15. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
Pitini V; Sturniolo G; Cavallari V; Arrigo C
Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
[No Abstract] [Full Text] [Related]
16. Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib.
Kim DS; Lee S; Choi CW
Korean J Intern Med; 2018 May; 33(3):642-644. PubMed ID: 28651427
[No Abstract] [Full Text] [Related]
17. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
18. Unique association of myeloid neoplasm with eosinophilia and abnormalities of PDGFRA with TTP.
Chaudhary LN; Bailey NG; Vos JA; Stotler CJ
W V Med J; 2013; 109(2):6-9. PubMed ID: 23600098
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
[TBL] [Abstract][Full Text] [Related]
20. "Likely to be missed if unsuspected":
Sharma P; Khaire NS; Sreedharanunni S; Malhotra P; Varma N
J Cancer Res Ther; 2022; 18(1):316-317. PubMed ID: 35381811
[No Abstract] [Full Text] [Related]
[Next] [New Search]
